Dasatinib, which targets a variety of tyrosine kinases, most notably the BCR/ABL fusion protein and the Src Family Kinases (SFKs), is used for the treatment of BCR/ABL+ CML and acute lymphocytic leukemia with imatinib resistance or intolerance to previous therapy [9], [10], [11], [12]. This evidence concerns the gene BCR and acute lymphoblastic leukemia.